Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination With Durvalumab and in Combination With Cabazitaxel and Durvalumab in Patients Who Have Progressive Metastatic Castrate-Resistant Prostate Cancer (AARDVARC)

NCT04495179 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04495179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04495179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination With Durvalumab and in Combination With Cabazitaxel and Durvalumab in Patients Who Have Progressive Metastatic Castrate-Resistant Prostate Cancer (AARDVARC)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
August 4, 2020
Completion date
August 8, 2022
Enrollment
30 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

progressive metastatic castrate-resistant prostate cancer